Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jan 29;26(3):708.
doi: 10.3390/molecules26030708.

New 1,2,3-Triazole-Containing Hybrids as Antitumor Candidates: Design, Click Reaction Synthesis, DFT Calculations, and Molecular Docking Study

Islam H El Azab  1   2 , Hamdy S El-Sheshtawy  3 , Rania B Bakr  4   5 , Nadia A A Elkanzi  2   6
Affiliations

New 1,2,3-Triazole-Containing Hybrids as Antitumor Candidates: Design, Click Reaction Synthesis, DFT Calculations, and Molecular Docking Study

Islam H El Azab et al. Molecules. .

Abstract

In an effort to improve and achieve biologically active anticancer agents, a novel series of 1,2,3-triazole-containing hybrids were designed and efficiently synthesized via the Cu-catalyzed azide-alkyne cycloaddition (CuAAC) reaction of substituted-arylazides with alkyne-functionalized pyrazole-[1,2,4]-triazole hybrids. The structure geometry of these new clicked 1,2,3-triazoles was explored by density functional theory (DFT) using the B3LYP/6-311++G(d,p) level; also, the potential activity of the compounds for light absorption was simulated by time-dependent DFT calculations (TD-DFT). The antitumor impacts of the newly synthesized compounds were in vitro estimated to be towards the human liver cancer cell line (HepG-2), the human colon cancer cell line (HCT-116), and human breast adenocarcinoma (MCF-7). Among the tested compounds, conjugate 7 was the most potent cytotoxic candidate towards HepG-2, HCT-116, and MCF-7, with IC50 = 12.22, 14.16, and 14.64 µM, respectively, in comparison to that exhibited by the standard drug doxorubicin (IC50 = 11.21, 12.46, and 13.45 µM). Finally, a molecular docking study was conducted within the epidermal growth factor receptor (EGFR) active site to suggest possible binding modes. Hence, it could conceivably be hypothesized that analogies 7, 6, and 5 could be considered as decent lead candidate compounds for anticancer agents.

Keywords: 1,2,3-triazole; DFT calculation; antitumor activity; click chemistry; cycloaddition reaction; molecular docking; pyrazole.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Representative samples of bioactive triazoles.
Scheme 1
Scheme 1
Reagents and conditions: (a) NaBH4, dry MeOH, stirring, rt, 1 h; (b) propargyl bromide, DMF, K2CO3, reflux/ stirring, 6 h; (c) Na-ascorbate, CuSO4·5H2O, DMF: H2O (6:1), stirring, 60–70 °C, 5–7 h.
Figure 2
Figure 2
Optimized structure of 8 and 9 derivatives at the B3LYP/6-311++G(d,p) level of theory in the gas phase.
Figure 3
Figure 3
(A) Simulated absorption spectra of compounds 7 and 9 calculated by TD-DFT in the gas phase and H2O, (B) Simulated absorption spectra of 9 in the gas phase and H2O at longer wavelength
Figure 4
Figure 4
In vitro anticancer effects of the target compounds on the HepG-2, HCT-116, and MCF-7 cell lines.
Figure 5
Figure 5
Docking of lapatinib within the ATP binding site of EGFR: (A) 3D binding mode; (B) 2D binding mode.
Figure 6
Figure 6
Docking of compound 7 within the ATP binding site of EGFR: (A) 3D binding mode; (B) 2D binding mode.
See this image and copyright information in PMC

References

    1. Sangthong S., Krusong K., Ngamrojanavanich N., Vilaivan T., Puthong S., Chandchawan S., Muangsin N. Synthesis of rotenoid derivatives with cytotoxic and topoisomerase II inhibitory activities. Bioorg. Med. Chem. Lett. 2011;21:4813–4818. doi: 10.1016/j.bmcl.2011.06.052. - DOI - PubMed
    1. Popiołek Ł., Biernasiuk A., Paruch K., Malm A., Wujec M. Synthesis and in vitro antimicrobial activity screening of new pipemidic acid derivatives. Arch. Pharm. Res. 2018;41:633–645. doi: 10.1007/s12272-018-1025-3. - DOI - PMC - PubMed
    1. Xu Z., Zhao S.-J., Liu Y. 1,2,3-Triazole-containing hybrids as potential anticancer agents: Current developments, action mechanisms and structure-activity relationships. Eur. J. Med. Chem. 2019;183:111700–111713. doi: 10.1016/j.ejmech.2019.111700. - DOI - PubMed
    1. Boraei A.T., Gomaa M.S., El Sayed H., Duerkop A. Design, selective alkylation and X-ray crystal structure determination of dihydro-indolyl-1,2,4-triazole-3-thione and its 3-benzylsulfanyl analogue as potent anticancer agents. Eur. J. Med. Chem. 2017;125:360–371. doi: 10.1016/j.ejmech.2016.09.046. - DOI - PubMed
    1. Aouad M.R., Mayaba M.M., Naqvi A., Bardaweel S.K., Al-blewi F.F., Messali M., Rezki N. Design, synthesis, in silico and in vitro antimicrobial screenings of novel 1,2,4-triazoles carrying 1,2,3-triazole scaffold with lipophilic side chain tether. Chem. Cent. J. 2017;11:117–123. doi: 10.1186/s13065-017-0347-4. - DOI - PMC - PubMed

MeSH terms